m6A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling

Abstract

Background Pancreatic cancer is one of the most lethal types of cancer with extremely poor diagnosis and prognosis, and chemo-resistance remains a major challenge. The dynamic and reversible N 6 -methyladenosine (m 6 A) RNA modification has emerged as a new layer of epigenetic gene regulation. Methods qRT-PCR and IHC were applied to examine ALKBH5 levels in normal and pancreatic cancer tissues. Cancer cell proliferation and chemo-resistance were evaluated by clonogenic formation, chemosensitivity detection, and Western blotting assays. m 6 A-seq was performed to identify target genes. We evaluated the inhibitory effect of ALKBH5 in both in vivo and in vitro models. Results Here, we show that m 6 A demethylase ALKBH5 is downregulated in gemcitabine-treated patient-derived xenograft (PDX) model and its overexpression sensitized pancreatic ductal adenocarcinoma (PDAC) cells to chemotherapy. Decreased ALKBH5 levels predicts poor clinical outcome in PDAC and multiple other cancers. Furthermore, silencing ALKBH5 remarkably increases PDAC cell proliferation, migration, and invasion both in vitro and in vivo, whereas its overexpression causes the opposite effects. Global m 6 A profile revealed altered expression of certain ALKBH5 target genes, including Wnt inhibitory factor 1 ( WIF-1 ), which is correlated with WIF-1 transactivation and mediation of the Wnt pathway. Conclusions Our work uncovers the tumor suppressive and chemo-sensitizing function for ALKBH5, which provides insight into critical roles of m 6 A methylation in PDAC.

Full text

We don’t show the text of a retracted or withdrawn paper. The record stays, so citations to it can be checked.

Cited by papers we hold 15

• Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance · 2025
  No notice
• RNA modifications in cellular metabolism: implications for metabolism-targeted therapy and immunotherapy · 2024
  No notice
• The role of m6A methylation in therapy resistance in cancer · 2023
  No notice
• m6A modification: recent advances, anticancer targeted drug discovery and beyond · 2022
  No notice
• Demethylase ALKBH5 suppresses invasion of gastric cancer via PKMYT1 m6A modification · 2022
  No notice
• FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner · 2022
  No notice
• Role of m6A writers, erasers and readers in cancer · 2022
  No notice
• RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential · 2022
  No notice
• The role of m6A RNA methylation in cancer metabolism · 2022
  No notice
• The m6A RNA methylation regulates oncogenic signaling pathways driving cell malignant transformation and carcinogenesis · 2021
  No notice
• The role of m6A, m5C and Ψ RNA modifications in cancer: Novel therapeutic opportunities · 2021
  No notice
• ALKBH5 suppresses malignancy of hepatocellular carcinoma via m6A-guided epigenetic inhibition of LYPD1 · 2020
  No notice
• The biological function of m6A demethylase ALKBH5 and its role in human disease · 2020
  No notice
• The potential role of RNA N6-methyladenosine in Cancer progression · 2020
  No notice
• Upregulation of METTL14 mediates the elevation of PERP mRNA N6 adenosine methylation promoting the growth and metastasis of pancreatic cancer · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.